VBL Therapeutics Launches First Israeli Site as Part of the GLOBE International Pivotal Trial for VB-111

VBL Therapeutics (NASDAQ:VBLT) announced enrollment of the first patient in Israel, as part of the GLOBE Phase 3 pivotal trial for lead candidate VB-111.
According to the company:

The trial, which was commenced in the US in August 2015, is comparing VB-111 in combination with bevacizumab (Avastin^®) to bevacizumab alone in recurrent glioblastoma (rGBM). GLOBE has been designed to recruit approximately 252 patients in the US, Canada and Israel, and is expected to include 6 leading Israeli medical centers.

Tzahala Tzuk-Shina, MD, Head of the Neuro-oncology Unit, Rambam Health Care Campus, Haifa, Israel commented:

The huge unmet need for an effective therapy in glioblastoma warrants clinical evaluation of novel therapies. We are proud to be the first Israeli clinical site in this important rGBM trial and will continue our efforts to provide patients with access to innovative clinical options such as VB-111.

Click here to view the full press release.